Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of
MPM will improve overall survival and quality of life beyond that achieved with chemotherapy
alone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Collaborators:
Groupe Francais De Pneumo-Cancerologie University Hospital, Caen